ArticleScientific reports2017
Identification of a six-lncRNA signature associated with recurrence of ovarian cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Long noncoding RNAs in female malignancies: critical review of molecular mechanisms, clinical gaps, and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- LncRNAs in Ovarian Cancer: Emerging Insights and Future Perspectives in Tumor Biology and Clinical Applications.Cancers · 2026Review
- Long Non-Coding RNAs in Ovarian Cancer: Mechanistic Insights and Clinical Applications.Cancers · 2025Review
- A diagnostic miRNA panel to detect recurrence of ovarian cancer through artificial intelligence approaches.Journal of cancer research and clinical oncology · 2023Article
- The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer.Journal of ovarian research · 2022Article
- LncRNA RUNX1-IT1 affects the differentiation of Th1 cells by regulating NrCAM transcription in Graves' disease.Cell cycle (Georgetown, Tex.) · 2022Article
- N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.Hereditas · 2022Article
- LncRNA MATN1-AS1 for Prediction of Prognosis in Osteosarcoma Patients and Its Cellular Function.Molecular biotechnology · 2022Article
- Review
- Long non-coding RNA-H19 promotes ovarian cancer cell proliferation and migration via the microRNA-140/Wnt1 axis.The Kaohsiung journal of medical sciences · 2021Article
- Ovarian cancer: epigenetics, drug resistance, and progression.Cancer cell international · 2021Review
- Study and Characterization of Long Non-coding RUNX1-IT1 among Large Artery Atherosclerosis Stroke Patients Based on the ceRNA Hypothesis.Journal of molecular neuroscience : MN · 2021Article
- LncRNA HOTAIRM1, miR-433-5p and PIK3CD function as a ceRNA network to exacerbate the development of PCOS.Journal of ovarian research · 2021Article
- A Potential Immune-Related Long Non-coding RNA Prognostic Signature for Ovarian Cancer.Frontiers in genetics · 2021Article
- Long Noncoding RNAs as Innovative Urinary Diagnostic Biomarkers.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Article
- Advancing Pan-cancer Gene Expression Survial Analysis by Inclusion of Non-coding RNA.RNA biology · 2020Article
- The Interplay between Long Noncoding RNAs and Proteins of the Epigenetic Machinery in Ovarian Cancer.Cancers · 2020Review
- A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.BMC medical informatics and decision making · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OvCa) is the leading cause of death among all gynecological malignancies, and recurrent OvCa is almost always incurable. In this study, we developed a signature based on long non-coding RNAs (lncRNAs) associated with OvCa recurrence to facilitate personalized OvCa therapy. lncRNA expression data were extracted from GSE9891 and GSE30161. LASSO (least absolute shrinkage and selection operator) penalized regression was used to identify an lncRNA-based signature using the GSE9891 training cohort. The signature was then validated in GSE9891 internal and GSE30161 external validation cohorts. The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to explore the possible functions of identified lncRNAs. A six-lncRNA signature (RUNX1-IT1, MALAT1, H19, HOTAIRM1, LOC100190986 and AL132709.8) was identified in the training cohort and validated in internal and external validation cohorts using the LASSO method (P < 0.05). This signature was also independent of other clinical factors according to multivariate and sub-group analyses. The identified lncRNAs are involved in cancer-related biological processes and pathways. We selected a highly reliable signature based on six lncRNAs associated with OvCa recurrence. This six-lncRNA signature is a promising method to personalize ovarian cancer therapy and may improve patient quality of life quality according to patients' condition in the future.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.